AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03299751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diagnostic performances of biomarkers combination
Description: A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.
Study NCT04318951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive communicative-pragmatic social interaction.
Description: ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the \[...\]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks.
Study NCT04318951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care.
Description: Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
Study NCT04318951 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care.
Description: Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
Study NCT02545322 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Follow-up CT scans during week 3 and week 5 of treatment
Description: Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
Study NCT04162223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat injection of Recombivax-HB
Description: Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
Study NCT04162223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of Recombivax-HB
Description: Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
Study NCT03208322 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT02583035 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse telephone contact
Description: Nurse will contact patient 3 days before consultation
Study NCT00298909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: physical exercise
Study NCT00298909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niaspan (extended-release niacin)
Description: niaspan (extended-release niacin)
Study NCT00298909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin
Description: niacin extended-release
Study NCT00298909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: control
Study NCT04051788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step Aerobics
Description: Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
Study NCT04051788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise (Lower limb Cycling)
Description: Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
Study NCT01215500 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT
Description: RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~1. 8 Gy/ fraction x 3 fractions = 24 Gy~2. 10 Gy/fraction x 3 fractions = 30 Gy~3. 12 Gy/fraction x 3 fractions = 36 Gy~4. 14 Gy/fraction x 3 fractions = 42 Gy~5. 16 Gy/fraction x 3 fractions = 48 Gy~6. 18 Gy/fraction x 3 fractions = 52 Gy~7. 20 Gy/fraction x 3 fractions = 60 Gy
Study NCT04260009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets
Study NCT04260009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib AAF
Description: Brigatinib age-appropriate formulation (AAF)
Study NCT03318809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986
Description: tablets for oral administration
Study NCT03318809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 986
Description: tablets for oral administration
Study NCT03525990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
Study NCT03525990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
Study NCT00307125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus immunosuppression
Description: Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific.
Study NCT00307125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus immunosuppression
Description: Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific.
Study NCT02007889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: 50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
Study NCT03837379 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT03837379 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Goal2Quit + NRT Sampling
Description: Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT01134016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded.
Study NCT03545009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrate
Description: 70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
Study NCT03545009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice no Nitrate
Description: 70ml Concentrated Beetroot Juice with nitrate removed
Study NCT03545009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice
Description: 70ml Concentrated Beetroot Juice
Study NCT00934141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning Session
Description: Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
Study NCT00934141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interest Circle Calls
Description: Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
Study NCT00934141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
Study NCT00934141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
Study NCT00529022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.
Study NCT00529022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg by mouth Daily for 7 days.
Study NCT00529022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein on Days 3 and 10 over 60 Minutes.
Study NCT01106404 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RestoreSensor Neurostimulation System
Description: Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF.
Study NCT00639561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g of fibres per day
Description: 10 g of fibres per day
Study NCT00639561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g of fibres per day
Description: 40g of fibres per day
Study NCT03580772 — intervention group
Intervention type: DEVICE
Intervention: Persona TKR
Description: Persona® TKR (Zimmer Biomet)
Study NCT03580772 — intervention group
Intervention type: DEVICE
Intervention: Attune TKR
Description: Attune® TKR (Depuy synthes)
Study NCT02080455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 20 mg dose
Study NCT02080455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg
Study NCT02389114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Protein
Description: Soy protein is commonly consumed in Asian diet.
Study NCT02389114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy Protein
Description: Soy protein is commonly consumed in Asian diet.
Study NCT02389114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
Study NCT04005417 — intervention group
Intervention type: DRUG
Intervention: Stannous fluoride dentifrice
Description: Stannous fluoride (0.454%) dentifrice
Study NCT04005417 — intervention group
Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing potassium nitrate or arginine.
Study NCT04005417 — intervention group
Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study NCT01585636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose
Study NCT02039960 — intervention group
Intervention type: DRUG
Intervention: Bupropion
Description: Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
Study NCT04157140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
Study NCT04157140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE+RFA
Description: TACE first, followed by RFA within day7（+/-3days）
Study NCT00991263 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT00991263 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT00991263 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT02491268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Study NCT02491268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00565942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrative care
Description: In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
Study NCT00565942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
Study NCT02469896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IV Infusion
Study NCT02469896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Infusion
Study NCT04174456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: baseline and 6-month follow-up FDG PET
Study NCT04174456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FDG PET
Description: baseline and 6-month follow-up FDG PET
Study NCT03196986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mil60
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
Study NCT03196986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
Study NCT03015792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03015792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03015792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03015792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT03015792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03015792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01136811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer assisted surgery
Description: use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure
Study NCT02441062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-DOTATOC PET/CT
Description: Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
Study NCT02113384 — intervention group
Intervention type: OTHER
Intervention: Observational study.
Description: Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
Study NCT05429333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-assisted personalized diet
Description: The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings.
Study NCT03015441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Milk product fermented by lactic bacteria or not fermented
Description: 2 pots of 125g consumed daily during 28 days
Study NCT04254185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple decompression
Description: Surgical technique
Study NCT04254185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous anterior transposition
Description: Surgical technique
Study NCT01068353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg given as a once weekly subcutaneous injection
Study NCT01068353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection given once weekly